Mayo Clinic Uncovers 1 New Immune Step for Cancer Therapies
Updated
Updated · ABC 6 News KAAL TV · Jun 24
Mayo Clinic Uncovers 1 New Immune Step for Cancer Therapies
1 articles · Updated · ABC 6 News KAAL TV · Jun 24
Summary
Mayo Clinic researchers identified a previously unknown step in how cancer-fighting immune cells prepare to attack tumors, a finding that could improve immunotherapy design.
The work helps explain why some cancer immunotherapies trigger strong early responses but lose effectiveness over time as those immune cells fail to remain durable.
Future treatments may need to balance 2 goals—boosting anti-tumor activity and preserving the long-term staying power of immune cells.
Researchers said more studies are still needed to determine how the discovery translates to patients, but it points to a new path for improving cancer outcomes.
Could recharging immune cell 'batteries' be the key to defeating treatment-resistant cancers?
Can AI predict when a patient's immune system will run out of energy before treatment starts?
Enhancing T-Cell Resilience with NKG7: Transforming Cancer Treatment Outcomes
Overview
In 2025, the Mayo Clinic discovered that the protein NKG7 plays a crucial role in making T cells more resilient and effective against tumors. By adding NKG7 to CD8+ T cell therapies like CAR-T and TIL, these immune cells gain a robust and enduring 'resilient phenotype,' helping them maintain their cancer-killing functions even in the stressful tumor environment. This breakthrough addresses a major limitation of current immunotherapies, where T cells often become exhausted and lose effectiveness, leading to short-lived responses and cancer relapse. As a result, NKG7-enhanced therapies promise improved patient outcomes.